Johnson & Johnson (JNJ) stock
NYSE
As of the Nov 6, 2026 close (U.S. Eastern)
- Market cap
- $664.9B
- As of Nov 6, 2026
- P/E
- 41.31x
- Trailing twelve months
- P/B
- 8.15x
- Latest reported equity
- P/S
- 6.69x
- Trailing twelve months
- ROE
- 19.7%
- Trailing twelve months
- Dividend yield
- 1.86%
- Latest fiscal-year dividends
Multiples use the price as of Nov 6, 2026 and may differ from the current price.
- Market cap
- $664.9B
- As of Nov 6, 2026
- P/E
- 41.31x
- Trailing twelve months
- P/B
- 8.15x
- Latest reported equity
- P/S
- 6.69x
- Trailing twelve months
- ROE
- 19.7%
- Trailing twelve months
- Dividend yield
- 1.86%
- Latest fiscal-year dividends
Multiples use the price as of Nov 6, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 6, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
41.31x
P/B
8.15x
P/S
6.69x
Earnings and dividend metrics▾
Earnings
EPS
$6.69
Earnings per share
BPS
$33.87
Book value per share
ROE
19.7%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $6.69 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $33.87 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 19.7%.
Dividends
Yield
1.86%
Dividend per share
$5.14
Payout ratio
76.9%
Consecutive years
5+ yrs
Yield uses fiscal 2025 dividends · Dividend per share and payout ratio are for fiscal 2025.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $514.00 before tax.
- Payout ratio — 76.9% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 5 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 5.9% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $24B+5.9%
$22.5B
Jul–Sep '24
$24B
Jul–Sep '25
$25.4B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 21, 2026.
- Earnings per share decreased 95.8% from the same quarter a year earlier.
- Revenue increased 5.9% from the same quarter a year earlier.
- Net income decreased 95.9% from the same quarter a year earlier.
Filed Oct 21, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Schmid TimothyEVP, WW Chair, MedTech · Sep 2, 2026Open-market sale33,597 shares · $9.2MAvg. price $274.7425,447 shares held after
Show 2 price lots
- 22,527 shares × $274.74$6.2M
- 11,070 shares × $274.74$3.0M
- Schmid TimothyEVP, WW Chair, MedTech · Sep 2, 2026Option exercise33,597 shares · $4.9MAvg. price $144.9948
Show 2 price lots
- 22,527 shares × $151.41$3.4M
- 11,070 shares × $131.94$1.5M
- Taubert Jennifer LEVP, WWC. Innovative Medicine · Aug 17, 2026Open-market sale15,000 shares · $4.0MAvg. price $263.36194,451 shares held after
- Taubert Jennifer LEVP, WWC. Innovative Medicine · Aug 17, 2026Option exercise15,000 shares · $1.7MAvg. price $115.67209,451 shares held after
- Duato JoaquinCEO and Chairman of the Board · Aug 13, 2026Open-market sale123,291 shares · $32.2MAvg. price $261.1701
Show 2 price lots
- 102,315 shares × $261$26.7M
- 20,976 shares × $262$5.5M
- Duato JoaquinCEO and Chairman of the Board · Aug 13, 2026Option exercise123,291 shares · $14.3MAvg. price $115.67399,258 shares held after
- Forminard ElizabethEVP, Chief Legal Officer · Aug 6, 2026Open-market sale15,918 shares · $4.1MAvg. price $257.0021
Show 2 price lots
- 9,344 shares × $257.755$2.4M
- 6,574 shares × $255.932$1.7M
- Forminard ElizabethEVP, Chief Legal Officer · Aug 6, 2026Option exercise9,344 shares · $1.2MAvg. price $131.9432,912 shares held after
- Duato JoaquinCEO and Chairman of the Board · Aug 5, 2026Open-market sale48,480 shares · $12.5MAvg. price $258.1479
Show 2 price lots
- 41,957 shares × $258.056$10.8M
- 6,523 shares × $258.739$1.7M
- Broadhurst VanessaEVP, Global Corp Affairs · Jul 20, 2026Open-market sale23,054 shares · $5.8MAvg. price $251.26623,003 shares held after
- Broadhurst VanessaEVP, Global Corp Affairs · Jul 20, 2026Option exercise23,054 shares · $3.0MAvg. price $130.767
Show 2 price lots
- 11,925 shares × $131.94$1.6M
- 11,129 shares × $129.51$1.4M
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QJohnson & Johnson said worldwide sales for the Q3 quarter of 2026 were $25.4 billion, a total increase of 5.9%, with operational growth of 6.0%. The company also cited the impact of biosimilar competition on STELARA sales decline as approximately 4.2% of worldwide operational sales.Published Oct 21, 2026 · Filed Oct 21, 2026Read the summary →
- AI summary8-KThe company said Reported Sales for Q3 2026 rose 5.9% to $25,399 million, while net earnings of $210 million (diluted EPS of $0.09) fell 95.9% and 95.8%, respectively, from $5,152 million (EPS of $2.12) a year earlier.Published Oct 13, 2026 · Filed Oct 13, 2026Read the summary →
- AI summary8-KThe company said reported sales for Q2 2026 were $25,310 million, up 6.6% from $23,743 million a year earlier, and operational growth was 5.6%.Published Oct 2, 2026 · Filed Jul 15, 2026Read the summary →
- Johnson & Johnson said worldwide sales for the Q3 quarter of 2026 were $25.4 billion, a total increase of 5.9%, with operational growth of 6.0%. The company also cited the impact of biosimilar competition on STELARA sales decline as approximately 4.2% of worldwide operational sales.Read the full analysis →
- The company said Reported Sales for Q3 2026 rose 5.9% to $25,399 million, while net earnings of $210 million (diluted EPS of $0.09) fell 95.9% and 95.8%, respectively, from $5,152 million (EPS of $2.12) a year earlier.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Johnson & Johnson (JNJ) stock information
NYSE
Johnson & Johnson (JNJ) is listed on NYSE. Its market capitalization is about $664.9B. On trailing-twelve-month earnings the P/E ratio is 41.31, and the P/B ratio is 8.15. Return on equity is 19.7%. These figures are computed in-house from official filings and are reference information only.
Johnson & Johnson — frequently asked questions
- What is the P/E ratio of Johnson & Johnson (JNJ)?
- On a trailing-twelve-month basis, JNJ trades at a P/E ratio of 41.31. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Johnson & Johnson?
- JNJ has a market capitalization of about $664.9B. The figure moves with the share price and is refreshed each trading day.
- Does Johnson & Johnson pay a dividend?
- JNJ has a dividend yield of about 1.86%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.